Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 153 of 153 entries
Sorted by: Best Match Show Resources per page
Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis.

Cancer research

Sendi H, Yazdimamaghani M, Hu M, Sultanpuram N, Wang J, Moody AS, McCabe E, Zhang J, Graboski A, Li L, Rojas JD, Dayton PA, Huang L, Wang AZ.
PMID: 34753773
Cancer Res. 2021 Nov 09; doi: 10.1158/0008-5472.CAN-21-2269. Epub 2021 Nov 09.

Liver metastasis is a leading cause of cancer morbidity and mortality. Thus, there has been strong interest in the development of therapeutics that can effectively prevent liver metastasis. One potential strategy is to utilize molecules that have broad effects...

Cite
Sendi H, Yazdimamaghani M, Hu M, et al. Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis. Cancer Res. 2021;doi: 10.1158/0008-5472.CAN-21-2269.
Sendi, H., Yazdimamaghani, M., Hu, M., Sultanpuram, N., Wang, J., Moody, A. S., McCabe, E., Zhang, J., Graboski, A., Li, L., Rojas, J. D., Dayton, P. A., Huang, L., & Wang, A. Z. (2021). Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis. Cancer research, . https://doi.org/10.1158/0008-5472.CAN-21-2269
Sendi, Hossein, et al. "Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis." Cancer research vol. (2021). doi: https://doi.org/10.1158/0008-5472.CAN-21-2269
Sendi H, Yazdimamaghani M, Hu M, Sultanpuram N, Wang J, Moody AS, McCabe E, Zhang J, Graboski A, Li L, Rojas JD, Dayton PA, Huang L, Wang AZ. Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis. Cancer Res. 2021 Nov 09; doi: 10.1158/0008-5472.CAN-21-2269. Epub 2021 Nov 09. PMID: 34753773.
Copy Download .nbib Format: NLM
Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?.

Clinical kidney journal

Ferro CJ, Berry M, Moody WE, George S, Sharif A, Townend JN.
PMID: 34950460
Clin Kidney J. 2021 Jul 06;14(12):2472-2482. doi: 10.1093/ckj/sfab103. eCollection 2021 Dec.

Screening for occult coronary artery disease in potential kidney transplant recipients has become entrenched in current medical practice as the standard of care and is supported by national and international clinical guidelines. However, there is increasing and robust evidence...

Cite
Ferro CJ, Berry M, Moody WE, et al. Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. Clin Kidney J. 2021;14(12):2472-2482doi: 10.1093/ckj/sfab103.
Ferro, C. J., Berry, M., Moody, W. E., George, S., Sharif, A., & Townend, J. N. (2021). Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. Clinical kidney journal, 14(12), 2472-2482. https://doi.org/10.1093/ckj/sfab103
Ferro, Charles J, et al. "Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?." Clinical kidney journal vol. 14,12 (2021): 2472-2482. doi: https://doi.org/10.1093/ckj/sfab103
Ferro CJ, Berry M, Moody WE, George S, Sharif A, Townend JN. Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. Clin Kidney J. 2021 Jul 06;14(12):2472-2482. doi: 10.1093/ckj/sfab103. eCollection 2021 Dec. PMID: 34950460; PMCID: PMC8690093.
Copy Download .nbib Format: NLM
Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis.

Cancer research

Sendi H, Yazdimamaghani M, Hu M, Sultanpuram N, Wang J, Moody AS, McCabe E, Zhang J, Graboski A, Li L, Rojas JD, Dayton PA, Huang L, Wang AZ.
PMID: 34753773
Cancer Res. 2022 Jan 01;82(1):105-113. doi: 10.1158/0008-5472.CAN-21-2269. Epub 2021 Nov 09.

Liver metastasis is a leading cause of cancer morbidity and mortality. Thus, there has been strong interest in the development of therapeutics that can effectively prevent liver metastasis. One potential strategy is to utilize molecules that have broad effects...

Cite
Sendi H, Yazdimamaghani M, Hu M, et al. Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer Res. 2021;82(1):105-113doi: 10.1158/0008-5472.CAN-21-2269.
Sendi, H., Yazdimamaghani, M., Hu, M., Sultanpuram, N., Wang, J., Moody, A. S., McCabe, E., Zhang, J., Graboski, A., Li, L., Rojas, J. D., Dayton, P. A., Huang, L., & Wang, A. Z. (2022). Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer research, 82(1), 105-113. https://doi.org/10.1158/0008-5472.CAN-21-2269
Sendi, Hossein, et al. "Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis." Cancer research vol. 82,1 (2022): 105-113. doi: https://doi.org/10.1158/0008-5472.CAN-21-2269
Sendi H, Yazdimamaghani M, Hu M, Sultanpuram N, Wang J, Moody AS, McCabe E, Zhang J, Graboski A, Li L, Rojas JD, Dayton PA, Huang L, Wang AZ. Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer Res. 2022 Jan 01;82(1):105-113. doi: 10.1158/0008-5472.CAN-21-2269. Epub 2021 Nov 09. PMID: 34753773; PMCID: PMC8732321.
Copy Download .nbib Format: NLM
Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Moody WE, Holloway B, Arumugam P, Gill S, Wahid YS, Boivin CM, Thomson LE, Berman DS, Armstrong MJ, Ferguson J, Steeds RP.
PMID: 32394403
J Nucl Cardiol. 2021 Dec;28(6):2876-2891. doi: 10.1007/s12350-020-02126-z. Epub 2020 May 11.

BACKGROUND: Although consensus-based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study sought to determine the...

Cite
Moody WE, Holloway B, Arumugam P, et al. Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. J Nucl Cardiol. 2020;28(6):2876-2891doi: 10.1007/s12350-020-02126-z.
Moody, W. E., Holloway, B., Arumugam, P., Gill, S., Wahid, Y. S., Boivin, C. M., Thomson, L. E., Berman, D. S., Armstrong, M. J., Ferguson, J., & Steeds, R. P. (2021). Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2876-2891. https://doi.org/10.1007/s12350-020-02126-z
Moody, William E, et al. "Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2876-2891. doi: https://doi.org/10.1007/s12350-020-02126-z
Moody WE, Holloway B, Arumugam P, Gill S, Wahid YS, Boivin CM, Thomson LE, Berman DS, Armstrong MJ, Ferguson J, Steeds RP. Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. J Nucl Cardiol. 2021 Dec;28(6):2876-2891. doi: 10.1007/s12350-020-02126-z. Epub 2020 May 11. PMID: 32394403; PMCID: PMC8709822.
Copy Download .nbib Format: NLM
Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Moody WE, Holloway B, Arumugam P, Gill S, Wahid YS, Boivin CM, Thomson LE, Berman DS, Armstrong MJ, Ferguson J, Steeds RP.
PMID: 32394403
J Nucl Cardiol. 2021 Dec;28(6):2876-2891. doi: 10.1007/s12350-020-02126-z. Epub 2020 May 11.

BACKGROUND: Although consensus-based guidelines support noninvasive stress testing prior to orthotopic liver transplantation (OLT), the optimal screening strategy for assessment of coronary artery disease in patients with end-stage liver disease (ESLD) is unclear. This study sought to determine the...

Cite
Moody WE, Holloway B, Arumugam P, et al. Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. J Nucl Cardiol. 2020;28(6):2876-2891doi: 10.1007/s12350-020-02126-z.
Moody, W. E., Holloway, B., Arumugam, P., Gill, S., Wahid, Y. S., Boivin, C. M., Thomson, L. E., Berman, D. S., Armstrong, M. J., Ferguson, J., & Steeds, R. P. (2021). Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 28(6), 2876-2891. https://doi.org/10.1007/s12350-020-02126-z
Moody, William E, et al. "Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study." Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 28,6 (2021): 2876-2891. doi: https://doi.org/10.1007/s12350-020-02126-z
Moody WE, Holloway B, Arumugam P, Gill S, Wahid YS, Boivin CM, Thomson LE, Berman DS, Armstrong MJ, Ferguson J, Steeds RP. Prognostic value of coronary risk factors, exercise capacity and single photon emission computed tomography in liver transplantation candidates: A 5-year follow-up study. J Nucl Cardiol. 2021 Dec;28(6):2876-2891. doi: 10.1007/s12350-020-02126-z. Epub 2020 May 11. PMID: 32394403.
Copy Download .nbib Format: NLM
Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging.

Journal of developmental origins of health and disease

Clarke GD, Li J, Kuo AH, Moody AJ, Nathanielsz PW.
PMID: 33349289
J Dev Orig Health Dis. 2021 Apr;12(2):203-219. doi: 10.1017/S2040174420001233. Epub 2020 Dec 22.

Cardiovascular diseases (CVD) are important consequences of adverse perinatal conditions such as fetal hypoxia and maternal malnutrition. Cardiac magnetic resonance imaging (CMR) can produce a wealth of physiological information related to the development of the heart. This review outlines...

Cite
Clarke GD, Li J, Kuo AH, et al. Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging. J Dev Orig Health Dis. 2020;12(2):203-219doi: 10.1017/S2040174420001233.
Clarke, G. D., Li, J., Kuo, A. H., Moody, A. J., & Nathanielsz, P. W. (2021). Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging. Journal of developmental origins of health and disease, 12(2), 203-219. https://doi.org/10.1017/S2040174420001233
Clarke, G D, et al. "Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging." Journal of developmental origins of health and disease vol. 12,2 (2021): 203-219. doi: https://doi.org/10.1017/S2040174420001233
Clarke GD, Li J, Kuo AH, Moody AJ, Nathanielsz PW. Cardiac magnetic resonance imaging: insights into developmental programming and its consequences for aging. J Dev Orig Health Dis. 2021 Apr;12(2):203-219. doi: 10.1017/S2040174420001233. Epub 2020 Dec 22. PMID: 33349289; PMCID: PMC7987688.
Copy Download .nbib Format: NLM
Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response.

Cancer drug resistance (Alhambra, Calif.)

Moody AS, Dayton PA, Zamboni WC.
PMID: 34796317
Cancer Drug Resist. 2021;4:382-413. doi: 10.20517/cdr.2020.94. Epub 2021 Jun 19.

Standard small molecule and nanoparticulate chemotherapies are used for cancer treatment; however, their effectiveness remains highly variable. One reason for this variable response is hypothesized to be due to nonspecific drug distribution and heterogeneity of the tumor microenvironment, which...

Cite
Moody AS, Dayton PA, Zamboni WC. Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer Drug Resist. 2021;4:382-413doi: 10.20517/cdr.2020.94.
Moody, A. S., Dayton, P. A., & Zamboni, W. C. (2021). Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer drug resistance (Alhambra, Calif.), 4382-413. https://doi.org/10.20517/cdr.2020.94
Moody, Amber S, et al. "Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response." Cancer drug resistance (Alhambra, Calif.) vol. 4 (2021): 382-413. doi: https://doi.org/10.20517/cdr.2020.94
Moody AS, Dayton PA, Zamboni WC. Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response. Cancer Drug Resist. 2021;4:382-413. doi: 10.20517/cdr.2020.94. Epub 2021 Jun 19. PMID: 34796317; PMCID: PMC8597952.
Copy Download .nbib Format: NLM
Cellular dormancy in minimal residual disease following targeted therapy.

Breast cancer research : BCR

Ruth JR, Pant DK, Pan TC, Seidel HE, Baksh SC, Keister BA, Singh R, Sterner CJ, Bakewell SJ, Moody SE, Belka GK, Chodosh LA.
PMID: 34088357
Breast Cancer Res. 2021 Jun 04;23(1):63. doi: 10.1186/s13058-021-01416-9.

BACKGROUND: Breast cancer mortality is principally due to tumor recurrence, which can occur following extended periods of clinical remission that may last decades. While clinical latency has been postulated to reflect the ability of residual tumor cells to persist...

Cite
Ruth JR, Pant DK, Pan TC, et al. Cellular dormancy in minimal residual disease following targeted therapy. Breast Cancer Res. 2021;23(1):63doi: 10.1186/s13058-021-01416-9.
Ruth, J. R., Pant, D. K., Pan, T. C., Seidel, H. E., Baksh, S. C., Keister, B. A., Singh, R., Sterner, C. J., Bakewell, S. J., Moody, S. E., Belka, G. K., & Chodosh, L. A. (2021). Cellular dormancy in minimal residual disease following targeted therapy. Breast cancer research : BCR, 23(1), 63. https://doi.org/10.1186/s13058-021-01416-9
Ruth, Jason R, et al. "Cellular dormancy in minimal residual disease following targeted therapy." Breast cancer research : BCR vol. 23,1 (2021): 63. doi: https://doi.org/10.1186/s13058-021-01416-9
Ruth JR, Pant DK, Pan TC, Seidel HE, Baksh SC, Keister BA, Singh R, Sterner CJ, Bakewell SJ, Moody SE, Belka GK, Chodosh LA. Cellular dormancy in minimal residual disease following targeted therapy. Breast Cancer Res. 2021 Jun 04;23(1):63. doi: 10.1186/s13058-021-01416-9. PMID: 34088357; PMCID: PMC8178846.
Copy Download .nbib Format: NLM
RUNX1 Regulates a Transcription Program That Affects the Dynamics of Cell Cycle Entry of Naive Resting B Cells.

Journal of immunology (Baltimore, Md. : 1950)

Thomsen I, Kunowska N, de Souza R, Moody AM, Crawford G, Wang YF, Khadayate S, Whilding C, Strid J, Karimi MM, Barr AR, Dillon N, Sabbattini P.
PMID: 34810221
J Immunol. 2021 Nov 22; doi: 10.4049/jimmunol.2001367. Epub 2021 Nov 22.

RUNX1 is a transcription factor that plays key roles in hematopoietic development and in hematopoiesis and lymphopoiesis. In this article, we report that RUNX1 regulates a gene expression program in naive mouse B cells that affects the dynamics of...

Cite
Thomsen I, Kunowska N, de Souza R, et al. RUNX1 Regulates a Transcription Program That Affects the Dynamics of Cell Cycle Entry of Naive Resting B Cells. J Immunol. 2021;doi: 10.4049/jimmunol.2001367.
Thomsen, I., Kunowska, N., de Souza, R., Moody, A. M., Crawford, G., Wang, Y. F., Khadayate, S., Whilding, C., Strid, J., Karimi, M. M., Barr, A. R., Dillon, N., & Sabbattini, P. (2021). RUNX1 Regulates a Transcription Program That Affects the Dynamics of Cell Cycle Entry of Naive Resting B Cells. Journal of immunology (Baltimore, Md. : 1950), . https://doi.org/10.4049/jimmunol.2001367
Thomsen, Inesa, et al. "RUNX1 Regulates a Transcription Program That Affects the Dynamics of Cell Cycle Entry of Naive Resting B Cells." Journal of immunology (Baltimore, Md. : 1950) vol. (2021). doi: https://doi.org/10.4049/jimmunol.2001367
Thomsen I, Kunowska N, de Souza R, Moody AM, Crawford G, Wang YF, Khadayate S, Whilding C, Strid J, Karimi MM, Barr AR, Dillon N, Sabbattini P. RUNX1 Regulates a Transcription Program That Affects the Dynamics of Cell Cycle Entry of Naive Resting B Cells. J Immunol. 2021 Nov 22; doi: 10.4049/jimmunol.2001367. Epub 2021 Nov 22. PMID: 34810221; PMCID: PMC8675107.
Copy Download .nbib Format: NLM
Showing 145 to 153 of 153 entries